6,857 research outputs found

    A Novel Chronic Disease Policy Model

    Full text link
    We develop a simulation tool to support policy-decisions about healthcare for chronic diseases in defined populations. Incident disease-cases are generated in-silico from an age-sex characterised general population using standard epidemiological approaches. A novel disease-treatment model then simulates continuous life courses for each patient using discrete event simulation. Ideally, the discrete event simulation model would be inferred from complete longitudinal healthcare data via a likelihood or Bayesian approach. Such data is seldom available for relevant populations, therefore an innovative approach to evidence synthesis is required. We propose a novel entropy-based approach to fit survival densities. This method provides a fully flexible way to incorporate the available information, which can be derived from arbitrary sources. Discrete event simulation then takes place on the fitted model using a competing hazards framework. The output is then used to help evaluate the potential impacts of policy options for a given population.Comment: 24 pages, 13 figures, 11 table

    Case-cohort studies with interval-censored failure time data

    Get PDF
    The case-cohort design has been widely used as a means of cost reduction in assembling or measuring expensive covariates in large cohort studies. The existing literature on the case-cohort design is mainly focused on right-censored data. In practice, however, the failure time is often subject to interval-censoring; it is known only to fall within some random time interval. In this paper, we consider the case-cohort study design for interval-censored failure time and develop a sieve semiparametric likelihood approach for analyzing data from this design under the proportional hazards model. We construct the likelihood function using inverse probability weighting and build the sieves with Bernstein polynomials. The consistency and asymptotic normality of the resulting regression parameter estimator are established and a weighted bootstrap procedure is considered for variance estimation. Simulations show that the proposed method works well for practical situations, and an application to real data is provided

    Age at quitting smoking as a predictor of risk of cardiovascular disease incidence independent of smoking status, time since quitting and pack-years

    Get PDF
    BACKGROUND Risk prediction for CVD events has been shown to vary according to current smoking status, pack-years smoked over a lifetime, time since quitting and age at quitting. The latter two are closely and inversely related. It is not known whether the age at which one quits smoking is an additional important predictor of CVD events. The aim of this study was to determine whether the risk of CVD events varied according to age at quitting after taking into account current smoking status, lifetime pack-years smoked and time since quitting. FINDINGS We used the Cox proportional hazards model to evaluate the risk of developing a first CVD event for a cohort of participants in the Framingham Offspring Heart Study who attended the fourth examination between ages 30 and 74 years and were free of CVD. Those who quit before the median age of 37 years had a risk of CVD incidence similar to those who were never smokers. The incorporation of age at quitting in the smoking variable resulted in better prediction than the model which had a simple current smoker/non-smoker measure and the one that incorporated both time since quitting and pack-years. These models demonstrated good discrimination, calibration and global fit. The risk among those quitting more than 5 years prior to the baseline exam and those whose age at quitting was prior to 44 years was similar to the risk among never smokers. However, the risk among those quitting less than 5 years prior to the baseline exam and those who continued to smoke until 44 years of age (or beyond) was two and a half times higher than that of never smokers. CONCLUSIONS Age at quitting improves the prediction of risk of CVD incidence even after other smoking measures are taken into account. The clinical benefit of adding age at quitting to the model with other smoking measures may be greater than the associated costs. Thus, age at quitting should be considered in addition to smoking status, time since quitting and pack-years when counselling individuals about their cardiovascular risk.This research was supported by an NHMRC health services research grant (no. 465130), an NHMRC/NHF PhD scholarship and a Vichealth Fellowship

    Stratified sampling design and loss to follow-up in survival models: evaluation of efficiency and bias

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Longitudinal studies often employ complex sample designs to optimize sample size, over-representing population groups of interest. The effect of sample design on parameter estimates is quite often ignored, particularly when fitting survival models. Another major problem in long-term cohort studies is the potential bias due to loss to follow-up.</p> <p>Methods</p> <p>In this paper we simulated a dataset with approximately 50,000 individuals as the target population and 15,000 participants to be followed up for 40 years, both based on real cohort studies of cardiovascular diseases. Two sample strategies - simple random (our golden standard) and Stratified by professional group, with non-proportional allocation - and two loss to follow-up scenarios - non-informative censoring and losses related to the professional group - were analyzed.</p> <p>Results</p> <p>Two modeling approaches were evaluated: weighted and non-weighted fit. Our results indicate that under the correctly specified model, ignoring the sample weights does not affect the results. However, the model ignoring the interaction of sample strata with the variable of interest and the crude estimates were highly biased.</p> <p>Conclusions</p> <p>In epidemiological studies misspecification should always be considered, as different sources of variability, related to the individuals and not captured by the covariates, are always present. Therefore, allowance must be made for the possibility of unknown confounders and interactions with the main variable of interest in our data. It is strongly recommended always to correct by sample weights.</p

    A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)

    Get PDF
    &lt;i&gt;Aims/hypothesis&lt;/i&gt; The aim of this study was to develop a simulation model for Type 2 diabetes that can be used to estimate the likely occurrence of major diabetes-related complications over a lifetime, in order to calculate health economic outcomes such as quality-adjusted life expectancy. &lt;i&gt;Methods&lt;/i&gt; Equations for forecasting the occurrence of seven diabetes-related complications and death were estimated using data on 3642 patients from the United Kingdom Prospective Diabetes Study (UKPDS). After examining the internal validity, the UKPDS Outcomes Model was used to simulate the mean difference in expected quality-adjusted life years between the UKPDS regimens of intensive and conventional blood glucose control. &lt;i&gt;Results&lt;/i&gt; The models forecasts fell within the 95% confidence interval for the occurrence of observed events during the UKPDS follow-up period. When the model was used to simulate event history over patients lifetimes, those treated with a regimen of conventional glucose control could expect 16.35 undiscounted quality-adjusted life years, and those receiving treatment with intensive glucose control could expect 16.62 quality-adjusted life years, a difference of 0.27 (95% CI: –0.48 to 1.03). &lt;i&gt;Conclusions/interpretations&lt;/i&gt; The UKPDS Outcomes Model is able to simulate event histories that closely match observed outcomes in the UKPDS and that can be extrapolated over patients lifetimes. Its validity in estimating outcomes in other groups of patients, however, remains to be evaluated. The model allows simulation of a range of long-term outcomes, which should assist in informing future economic evaluations of interventions in Type 2 diabetes
    • …
    corecore